# RAPCHEM: HCP commentary report

> 106 verified statements (24 from clinicians verified by NPI or staff page) from 30 commentary sources · 7 findings · updated Oct 31, 2026

## Report

- Trial: Radiotherapy After Primary CHEMotherapy for cT1-2cN1M0 Breast Cancer.: a Multicentre Prospective Registration Study.
- NCT ID: NCT01279304
- Registry: https://clinicaltrials.gov/study/NCT01279304
- Sponsor: Maastricht Radiation Oncology
- Phase: Observational
- Status: Completed
- Version: v1.0.0, edition 1
- Accepted: 2026-10-31
- Last checked: 2026-10-31
- Release hash: ec19a082d93cd2ebe3e572c3f7355107e560cfcb68bebb4f3fa3d72c44b7876c

## Counts

- HCP commentary sources screened: 58
- Sources cited by verified statements: 34
- Verified statements: 106
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 24
- Findings: 7
- Named people in screened sources (unnamed speakers and accounts not counted): 26
- Voices cited: 26
- Cited voices identity-verified: 17
- Organisational or shared accounts (not counted as people): 7

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

RAPCHEM asks whether nodal-response-guided radiotherapy reduction after chemotherapy and surgery can preserve locoregional control in selected cT1–2N1 breast cancer. Commentary comes from X, LinkedIn and Bluesky posts, as well as podcast interviews. Debate centers on whether low recurrence is enough to change radiotherapy practice, how patient selection and axillary surgery constrain de-escalation, and unresolved questions about endocrine treatment and late recurrence.

## Open Medical Affairs question

For which combinations of baseline risk, nodal response and axillary surgery is the evidence sufficient to discuss less radiotherapy, and what uncertainty should patients hear?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. The favorable interpretation depends on patient selection and the extent of axillary surgery
- F2. Low recurrence is persuasive to some authors, but not a shared threshold for changing practice
- F3. Late recurrence prompted an explicit, unresolved debate about endocrine treatment and follow-up
- F4. Response adaptation is interpreted as treatment precision, not chemotherapy replacing radiotherapy
- F5. NSABP B-51 and axillary-management evidence are invoked to define what RAPCHEM can support
- F6. Avoiding morbidity motivates support, but measured quality-of-life benefit is not established
- F7. An unnamed-trial interview broadens the question to biology-guided volumes and boost doses

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 13 | 8 | 6 | 7 | none recorded | 3 |
| F2 | 17 | 19 | 11 | 12 | recorded | 3 |
| F3 | 20 | 19 | 4 | 9 | recorded | 3 |
| F4 | 31 | 26 | 16 | 17 | recorded | 3 |
| F5 | 11 | 9 | 8 | 6 | recorded | 4 |
| F6 | 18 | 20 | 15 | 12 | recorded | 3 |
| F7 | 4 | 1 | 1 | 0 | none recorded | 4 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 8 | 5 | 0 | 0 | 0 | 14 | 0 | 5 posts and articles, 1 podcast or video | yes |
| F2 | 11 | 4 | 0 | 1 | 1 | 20 | 1 | 11 posts and articles | yes |
| F3 | 11 | 5 | 0 | 2 | 2 | 20 | 1 | 4 posts and articles | yes |
| F4 | 16 | 2 | 0 | 1 | 12 | 31 | 2 | 14 posts and articles, 2 podcasts and video | yes |
| F5 | 5 | 2 | 0 | 1 | 3 | 14 | 0 | 8 posts and articles | yes |
| F6 | 10 | 2 | 0 | 0 | 6 | 22 | 1 | 13 posts and articles, 1 podcast or video, 1 publication | yes |
| F7 | 1 | 1 | 0 | 1 | 1 | 5 | 1 | 1 podcast or video | yes |

### Trial dimensions

- Primary endpoint: locoregional recurrence rate: F1 (2 shared claims), F2 (7 shared claims), F3 (1 shared claims), F4 (9 shared claims), F5 (1 shared claims), F6 (3 shared claims)
- Secondary endpoints: F1 (3 shared claims), F2 (2 shared claims), F3 (5 shared claims), F4 (4 shared claims), F6 (3 shared claims)
- Population and setting: F1 (10 shared claims), F2 (2 shared claims), F3 (1 shared claims), F4 (9 shared claims), F5 (3 shared claims), F6 (1 shared claims)
- The comparison: F1 (5 shared claims), F2 (6 shared claims), F3 (1 shared claims), F4 (8 shared claims), F5 (6 shared claims), F6 (1 shared claims)
- Safety and tolerability: F1 (3 shared claims), F2 (3 shared claims), F4 (2 shared claims), F5 (1 shared claims), F6 (13 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

### F2. Low recurrence is persuasive to some authors, but not a shared threshold for changing practice

A LinkedIn post examined the role of RAPCHEM’s prospective registry design versus randomized trials in answering radiotherapy de-escalation questions.

Source: LinkedIn post, 2026-07-02.

### F1. The favorable interpretation depends on patient selection and the extent of axillary surgery

A LinkedIn post asked whether the RAPCHEM findings apply after sentinel-node biopsy alone or when axillary surgery is omitted.

Source: LinkedIn post, 2026-03-30.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 7 | Titles free |
| Detailed analysis | 8 sections | Paid |
| Verified statements with short source quotes and links | 106 | Paid |
| Trial aspects mapped | 11 | Free |
| Sources with links | 34 | Counts free |
| Speaker attribution for cited voices | 26 | Paid |

## Trial aspects

11 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: locoregional recurrence rate | discussed | 18 | 16 |
| Secondary endpoints | discussed | 14 | 9 |
| Population and setting | discussed | 17 | 8 |
| The comparison | discussed | 18 | 8 |
| Safety and tolerability | discussed | 14 | 11 |
| Evidence thresholds, pragmatic registries and practice uptake | discussed | 17 | 11 |
| Axillary surgery, treatment balance and guideline adherence | discussed | 8 | 5 |
| Tumor biology, late recurrence and endocrine-treatment explanations | discussed | 23 | 8 |
| Related evidence: NSABP B-51, A011202 and an unspecified Alliance study | discussed | 10 | 7 |
| Patient–clinician choices, treatment burden and the systemic-versus-local distinction | discussed | 13 | 7 |
| Unnamed-trial context: radiotherapy volumes and boosts after primary systemic therapy | discussed | 4 | 1 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 33 | 11 |
| LinkedIn posts | 16 | 13 |
| Bluesky threads | 6 | 3 |
| Podcasts | 2 | 2 |
| YouTube | 1 | 1 |
| Publications (primary source, cited for context) | not screened | 3 |
| Registry (primary source, cited for context) | not screened | 1 |

- Screened window: 2020-02-15 to 2026-08-19
- Cited window: 2022-08-10 to 2026-08-07
- Retrieved: 2026-10-31

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: Radiotherapy After Primary CHEMotherapy for cT1-2cN1M0 Breast Cancer.: a Multicentre Prospective Registration Study.
- Also known as: BOOG 2010-03
- Registry: NCT01279304 (https://clinicaltrials.gov/study/NCT01279304)
- Study IDs: 10-04-10/02
- Sponsor: Maastricht Radiation Oncology
- Collaborators: The Netherlands Cancer Institute, Diakonessenhuis, Utrecht
- Design: Observational · observational, cohort, prospective
- Status: Completed
- Enrollment: 851 (actual)
- Start: 2011-01
- Primary completion: 2017-12 (actual)
- Primary endpoint: locoregional recurrence rate (5 Yr)
- Intervention: radiation - no radiation see intervention description (radiation)
- Intervention: radiation: see intervention description (radiation)
- Intervention: radiation: see intervention description (radiation)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- The source search did not run to completion, so some matching discussion may be missing.
- For 1 recording, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.
- Not yet captured in this edition: a view on short-course radiotherapy versus omission for selected patients and how waiting lists and treatment aversion affect choices.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 37 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- This is an account of the sources reviewed for this edition, not a representative survey of HCP opinion or a measure of consensus. Organizational communications, presentation relays and reposts must not be counted as independent clinician views.
- The 2022 five-year discussions, preliminary NSABP B-51 commentary in December 2023 and 2026 ten-year discussions should not be treated as contemporaneous positions or evidence that any author changed practice.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- Some interview statements have no established speaker identity. Equivalent wording in another version of an interview does not authorize assigning the unnamed version to a named person.
- The May 2024 unnamed-trial interview contains unclear wording and does not establish a specific initial nodal category. Its views bear on response-adapted radiotherapy but are not RAPCHEM results.
- RAPCHEM’s response-defined groups and nonrandomized design do not isolate the causal effect of radiotherapy omission. Surgical intensity, response-related prognosis and variation in delivered radiotherapy qualify favorable interpretations.
- Potential reductions in morbidity and improved quality of life are not demonstrated comparative outcomes in the cited discussion; Portugal a speaker explicitly notes the absence of direct quality-of-life data.
- Patient totals differ across coverage: some presentation posts report 848, while later ten-year accounts report 838. The report preserves those differences rather than treating them as interchangeable.
- A separate protocol was not available among the reviewed sources. Registry methods and publication context do not resolve every treatment-detail question raised in commentary.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-31: current edition

Last checked for new commentary 2026-10-31. No corrections. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Focused (106 verified statements)
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $1,300
- 6 months of weekly updates: $1,900
- 12 months of weekly updates: $2,600
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (17 now), at most $750; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/rapchem-nct01279304
- Agents: POST https://www.erudio.com/api/orders with {"report": "rapchem-nct01279304", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=rapchem-01279304

## Cite

Erudio Health. RAPCHEM (NCT01279304): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 31, 2026. https://www.erudio.com/reports/rapchem-nct01279304

## Machine access

- JSON: https://www.erudio.com/reports/rapchem-nct01279304.json
- Markdown: https://www.erudio.com/reports/rapchem-nct01279304.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "rapchem-01279304"}`